InvestorsObserver
×
News Home

Do Traders Think IGM Biosciences Inc (IGMS) Can Turn Around Tuesday?

Tuesday, February 27, 2024 11:54 AM | InvestorsObserver Analysts

Mentioned in this article

Do Traders Think IGM Biosciences Inc (IGMS) Can Turn Around Tuesday?

The market has been down on IGM Biosciences Inc (IGMS) stock recently. IGMS gets a Bearish score from InvestorsObserver Stock Sentiment Indicator.

Sentiment Score - ,bearish
IGM Biosciences Inc has a Bearish sentiment reading. Find out what this means for you and get the rest of the rankings on IGMS!

What is Stock Sentiment?

Sentiment uses short term technical analysis to gauge whether a stock is desired by investors. As a technical indicator, it focuses on recent trends as opposed to the long term health of the underlying company. Updates for the company such as a earnings release can move the stock away from current trends. Sentiment is how investors, or the market, feels about a stock. There are lots of ways to measure sentiment. At the core, sentiment is pretty easy to understand. If a stock is going up, investors must be bullish, while if it is going down, sentiment is bearish. InvestorsObserver’s Sentiment Indicator looks at price trends over the past week and also considers changes in volume. Increasing volume can mean a trend is getting stronger, while decreasing volume can mean a trend is nearing a conclusion. For stocks that have options, our system also considers the balance between calls, which are often bets that the price will go up, and puts, which are frequently bets that the price will fall.

What's Happening With IGMS Stock Today?

IGM Biosciences Inc (IGMS) stock has gained 1.15% while the S&P 500 is down -0.06% as of 11:52 AM on Tuesday, Feb 27. IGMS has risen $0.16 from the previous closing price of $13.93 on volume of 55,699 shares. Over the past year the S&P 500 is up 27.22% while IGMS is down -32.97%. IGMS lost -$4.99 per share in the over the last 12 months. To see InvestorsObserver's Sentiment Score for IGM Biosciences Inc click here.

More About IGM Biosciences Inc

IGM Biosciences Inc is a biotechnology company engaged in the development of IgM antibody therapeutics for the treatment of cancer, infectious diseases, and autoimmune and inflammatory diseases. Its IgM antibody technology platform is suited for developing T cell engagers, receptor cross-linking agonists, and targeted cytokines. Its product candidate, IGM-2323, is a bispecific T cell engaging IgM antibody targeting CD20 and CD3 protein, IGM-8444, a combination with a chemotherapeutic agent such as irinotecan, gemcitabine, or venetoclax, and IGM-7354, a bispecific IgM antibody delivering interleukin-15 (IL-15) cytokines to PD-L1 expressing cells for the treatment of patients with solid and hematologic malignancies. Click Here to get the full Stock Report for IGM Biosciences Inc stock.

You May Also Like

Get the InvestorsObserver App

InvestorsObserver App
iOS App Android App